• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
New Simple and Fast Digital Screening Method for Minimal Hepatic Encephalopathy in Cirrhotic Patients.用于肝硬化患者轻微肝性脑病的新型简单快速数字筛查方法
United European Gastroenterol J. 2025 Jul;13(6):851-852. doi: 10.1002/ueg2.70028. Epub 2025 May 2.
2
Validation of the animal naming test for diagnosing minimal hepatic encephalopathy.用于诊断轻微肝性脑病的动物命名测试的验证
Rev Gastroenterol Mex (Engl Ed). 2025 Apr-Jun;90(2):192-198. doi: 10.1016/j.rgmxen.2025.05.003. Epub 2025 Jun 3.
3
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.L-鸟氨酸L-天冬氨酸用于预防和治疗肝硬化患者的肝性脑病。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD012410. doi: 10.1002/14651858.CD012410.pub2.
4
Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.日本隐匿性肝性脑病的当前管理与未来展望:一项全国性调查
J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232-0.
5
Systemic Inflammatory Response Syndrome全身炎症反应综合征
6
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.利福昔明预防和治疗肝硬化患者肝性脑病。
Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.
7
Short-Term Memory Impairment短期记忆障碍
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
10
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施:系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.

本文引用的文献

1
Minimal Hepatic Encephalopathy in Cirrhotic Patients: A New Simple and Fast Digital Screening Method.肝硬化患者的轻微肝性脑病:一种新的简单快速数字筛查方法
United European Gastroenterol J. 2025 Sep;13(7):1194-1204. doi: 10.1002/ueg2.70004. Epub 2025 Apr 15.
2
Other causes of neurocognitive impairment than covert hepatic encephalopathy (CHE) are very frequent, either alone or associated with CHE, in cirrhotic patients with cognitive complaints.除了隐匿性肝性脑病(CHE)之外,有认知障碍主诉的肝硬化患者,其神经认知功能障碍的其他病因很多,单独存在或与 CHE 相关。
Aliment Pharmacol Ther. 2024 Sep;60(6):749-764. doi: 10.1111/apt.18148. Epub 2024 Jul 7.
3
Diagnosis and management of hepatic encephalopathy: The French recommendations.肝性脑病的诊断与管理:法国建议
Liver Int. 2023 Apr;43(4):750-762. doi: 10.1111/liv.15510. Epub 2023 Jan 24.
4
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.EASL 临床实践指南:肝性脑病管理。
J Hepatol. 2022 Sep;77(3):807-824. doi: 10.1016/j.jhep.2022.06.001. Epub 2022 Jun 17.
5
Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.基于智能手机的Stroop测试EncephalApp用于隐匿性肝性脑病诊断的验证
Clin Gastroenterol Hepatol. 2015 Oct;13(10):1828-1835.e1. doi: 10.1016/j.cgh.2014.05.011. Epub 2014 May 17.
6
Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.酒精性肝硬化的临床病程:一项丹麦基于人群的队列研究。
Hepatology. 2010 May;51(5):1675-82. doi: 10.1002/hep.23500.
7
Minimal hepatic encephalopathy matters in daily life.轻微肝性脑病影响日常生活。
World J Gastroenterol. 2008 Jun 21;14(23):3609-15. doi: 10.3748/wjg.14.3609.

用于肝硬化患者轻微肝性脑病的新型简单快速数字筛查方法

New Simple and Fast Digital Screening Method for Minimal Hepatic Encephalopathy in Cirrhotic Patients.

作者信息

Mouri S, Thabut D

机构信息

Hepatogastroenterology Department, La Pitie-Salpetriere Hospital, AP-HP, Sorbonne Universite, Paris, France.

Brain-Liver Pitie-Salpetriere Study Group (BLIPS), Paris, France.

出版信息

United European Gastroenterol J. 2025 Jul;13(6):851-852. doi: 10.1002/ueg2.70028. Epub 2025 May 2.

DOI:10.1002/ueg2.70028
PMID:40317909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12269728/
Abstract

Covert hepatic encephalopathy (CHE) is a subtle yet significant neurological complication of liver diseases, especially in patients with cirrhosis. Although it lacks overt clinical signs, CHE severely impacts quality of life, increases accident risks, and has serious prognostic implications. It is characterized by neurocognitive symptoms detectable only through specialized neuropsychometric tests. CHE affects 30%-80% of cirrhotic patients and represents the early stage of hepatic encephalopathy, which is a predictor of mortality. Early diagnosis is essential to improve patient outcomes. The Psychometric Hepatic Encephalopathy Score (PHES) is the gold standard for diagnosing CHE, but it is time-consuming and requires specialized training. Other tests, like the Animal Naming Test (ANT), are simpler and more practical for screening minimal hepatic encephalopathy (MHE), though they lack specificity. The Stroop test shows promise as a quicker and reliable diagnostic tool, but still has limitations. Recent innovations include a smartphone-based self-screening method developed by Dobbermann et al., combining three digital tests: the Tip Test, Number Connection Test, and Modified Stroop Test. This approach correlates well with PHES, is independent of language skills, and is accessible for a diverse patient population, including those with color vision deficiencies. This tool offers a rapid and reliable way to screen for CHE even in home settings, potentially improving early detection and intervention. In conclusion, CHE is an underrecognized but critical condition that requires greater clinical attention. Current diagnostic tools have limitations, highlighting the need for more effective, practical methods. A multidisciplinary approach involving hepatologists, neurologists, and neuropsychologists is crucial to improve the diagnosis and management of CHE, ultimately enhancing patient outcomes.

摘要

隐匿性肝性脑病(CHE)是肝脏疾病中一种隐匿但严重的神经并发症,在肝硬化患者中尤为常见。尽管它缺乏明显的临床症状,但CHE严重影响生活质量,增加事故风险,并具有严重的预后意义。其特征是只有通过专门的神经心理测试才能检测到的神经认知症状。CHE影响30%-80%的肝硬化患者,是肝性脑病的早期阶段,也是死亡率的一个预测指标。早期诊断对于改善患者预后至关重要。心理测量肝性脑病评分(PHES)是诊断CHE的金标准,但它耗时且需要专门培训。其他测试,如动物命名测试(ANT),对于筛查轻微肝性脑病(MHE)更简单、更实用,尽管它们缺乏特异性。Stroop测试有望成为一种更快、更可靠的诊断工具,但仍有局限性。最近的创新包括Dobbermann等人开发的一种基于智能手机的自我筛查方法,该方法结合了三项数字测试:指尖测试、数字连接测试和改良Stroop测试。这种方法与PHES相关性良好,独立于语言技能,并且适用于包括色盲患者在内的不同患者群体。即使在家庭环境中,这种工具也提供了一种快速、可靠的CHE筛查方法,有可能改善早期检测和干预。总之,CHE是一种未被充分认识但至关重要的疾病,需要更多的临床关注。目前的诊断工具存在局限性,凸显了对更有效、实用方法的需求。肝病学家、神经学家和神经心理学家的多学科方法对于改善CHE的诊断和管理至关重要,最终可提高患者的治疗效果。